Latest Content

Dan Bell, chief strategy officer at Marken, discusses how biopharma companies and logistics teams are responding to the dual disruptors to global supply chain operations.

Dismissing the role of independent, outside experts in FDA decision-making weakens the drug review process.

A federal court’s decision to temporarily allow continued mail distribution of mifepristone underscores the ongoing legal and regulatory uncertainty surrounding abortion access.

Shah Capital escalates its pressure campaign against Novavax leadership, requesting changes and strategic overhauls amid ongoing performance concerns.

Phenomix CEO Mark Bagnall explains how GLP-1 users often face significant costs to deal with the side effects of GLP-1 usage.

Companion diagnostics are reshaping precision oncology, but clinical adoption continues to lag behind scientific progress due to regulatory, operational and reimbursement barriers.

Disruptions from the U.S.and Iran conflict moves across key transit routes and threatens the flow of active ingredients, price spikes, and heightened risk of drug shortages worldwide.

In today's Pharmaceutical Executive Daily, Novo Nordisk launches Wegovy HD nationwide across the U.S., Gilead Sciences agrees to acquire German antibody-drug conjugate biotech Tubulis for up to $5 billion, and Pharmaceutical Executive marks World Health Day 2026 with a collection of voices from industry leaders on what it means to stand with science.

The agentic model is emerging as a strategic tool to compress analysis timelines, coordinate cross-functional teams and surface competitive intelligence in real time.

Gilead Sciences’ acquisition of Tubulis underscores the intensifying industry focus on antibody-drug conjugates as a key frontier in oncology treatment.

Industry leaders highlight how evidence-based decision-making remains central as World Health Day 2026 emphasizes the theme of standing with science.

GLP-1 side effects can be serious, and Phenomix CEO Mark Bagnall discusses the impact they can have on patients, who are not always fully educated.

Where PBMs fit into the new market access landscape, how pharma companies can respond and the questions that remain.